CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

CytomX Therapeutics

06/08/2026 22:01

CytomX Therapeutics, Inc. CTMX.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of eight analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -13 cents to 12 cents per share.
Revenue fell 92.4% to $1.42 million from a year ago; analysts expected $12.31 million. 
CytomX Therapeutics, Inc.'s reported EPS for the quarter was a loss of 9 cents​.
The company reported a quarterly loss of $20.67 million.
CytomX Therapeutics, Inc. shares had fallen by 10.7% this quarter and lost 21.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 21.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for CytomX Therapeutics, Inc. is $12.00, about 72.1% above its last closing price of $3.35
This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.08
-0.09
Missed
Mar. 31 2026 
-0.12
-0.10
Beat
Dec. 31 2025 
-0.09
-0.22
Missed
Sep. 30 2025 
-0.05
-0.09
Missed